# XILIO THERAPEUTICS INC (XLO)

> Institutional ownership reported to the SEC as of Q2 2026, from Form 13F filings. Source: https://holderbook.com/stocks/XLO/

- Reporting holders: 27
- Reported value: $35.2M
- Shares held by institutions: 3,672,557 of 5,782,511 outstanding
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Bain Capital Life Sciences Investors, LLC](https://holderbook.com/funds/1703031-bain-capital-life-sciences-investors-llc/) | $6.4M | 664,021 | 0.4% | 2 |
| [GILEAD SCIENCES, INC.](https://holderbook.com/funds/882095-gilead-sciences-inc/) | $6.2M | 650,389 | 0.4% | 7 |
| [ORBIMED ADVISORS LLC](https://holderbook.com/funds/1055951-orbimed-advisors-llc/) | $5.7M | 592,300 | 0.1% | 1 |
| [Stonepine Capital Management, LLC](https://holderbook.com/funds/1440771-stonepine-capital-management-llc/) | $4.3M | 451,988 | 1.1% | 2 |
| [Frazier Life Sciences Management, L.P.](https://holderbook.com/funds/1892134-frazier-life-sciences-management-l-p/) | $4.0M | 422,505 | 0.1% | 2 |
| [VANGUARD CAPITAL MANAGEMENT LLC](https://holderbook.com/funds/2100119-vanguard-capital-management-llc/) | $1.7M | 178,517 | 0.0% | 2 |
| [Sio Capital Management, LLC](https://holderbook.com/funds/1482416-sio-capital-management-llc/) | $1.5M | 152,464 | 0.2% | 2 |
| [ADAGE CAPITAL PARTNERS GP, L.L.C.](https://holderbook.com/funds/1165408-adage-capital-partners-gp-l-l-c/) | $1.1M | 111,541 | 0.0% | 1 |
| [Merck & Co., Inc.](https://holderbook.com/funds/310158-merck-co-inc/) | $1.0M | 105,982 | 0.2% | 2 |
| [RENAISSANCE TECHNOLOGIES LLC](https://holderbook.com/funds/1037389-renaissance-technologies-llc/) | $614.6K | 64,153 | 0.0% | 2 |
| [MORGAN STANLEY](https://holderbook.com/funds/895421-morgan-stanley/) | $545.6K | 56,954 | 0.0% | 2 |
| [CITADEL ADVISORS LLC](https://holderbook.com/funds/1423053-citadel-advisors-llc/) | $497.2K | 51,900 | 0.0% | 1 |
| [GEODE CAPITAL MANAGEMENT, LLC](https://holderbook.com/funds/1214717-geode-capital-management-llc/) | $374.2K | 39,055 | 0.0% | 2 |
| [STATE STREET CORP](https://holderbook.com/funds/93751-state-street-corp/) | $255.0K | 26,622 | 0.0% | 2 |
| [VANGUARD FIDUCIARY TRUST CO](https://holderbook.com/funds/933478-vanguard-fiduciary-trust-co/) | $216.5K | 22,594 | 0.0% | 2 |
| [BRIDGEWAY CAPITAL MANAGEMENT, LLC](https://holderbook.com/funds/1107261-bridgeway-capital-management-llc/) | $168.1K | 17,544 | 0.0% | 1 |
| [TWO SIGMA INVESTMENTS, LP](https://holderbook.com/funds/1179392-two-sigma-investments-lp/) | $139.3K | 14,544 | 0.0% | 1 |
| [Velan Capital Investment Management LP](https://holderbook.com/funds/1848809-velan-capital-investment-management-lp/) | $136.8K | 14,285 | 0.1% | 2 |
| [GSA CAPITAL PARTNERS LLP](https://holderbook.com/funds/1362033-gsa-capital-partners-llp/) | $130.0K | 13,590 | 0.0% | 2 |
| [PRELUDE CAPITAL MANAGEMENT, LLC](https://holderbook.com/funds/1387508-prelude-capital-management-llc/) | $111.1K | 11,600 | 0.0% | 1 |
| [BlackRock, Inc.](https://holderbook.com/funds/2012383-blackrock-inc/) | $83.9K | 8,757 | 0.0% | 1 |
| [Steward Partners Investment Advisory, LLC](https://holderbook.com/funds/1723397-steward-partners-investment-advisory-llc/) | $6.8K | 714 | 0.0% | 1 |
| [SECURITY NATIONAL BANK OF SIOUX CITY IOWA /IA/](https://holderbook.com/funds/894309-security-national-bank-of-sioux-city-iowa-ia/) | $3.1K | 321 | 0.0% | 1 |
| [BARCLAYS PLC](https://holderbook.com/funds/312069-barclays-plc/) | $1.1K | 115 | 0.0% | 1 |
| [Key Financial Inc](https://holderbook.com/funds/1801720-key-financial-inc/) | $565 | 59 | 0.0% | 2 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q2 2026 | 27 | $35.2M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 32 | $11.4M |
| Q2 2024 | 30 | $12.4M |
| Q1 2024 | 30 | $12.4M |
| Q4 2023 | 32 | $8.3M |
| Q3 2023 | 30 | $30.4M |